Adagene (ADAG) Registration Filing summary

Company overview and business model

• Platform-driven, clinical-stage biotech focused on novel antibody-based cancer immunotherapies using proprietary Dynamic Precision Library (DPL) platform, including NEObody, SAFEbody, and POWERbody technologies.

• Lead candidate ADG126 (anti-CTLA-4 SAFEbody) in phase 1b/2 for metastatic MSS colorectal cancer; robust pipeline of earlier-stage candidates.

• Operations conducted through subsidiaries in the U.S., China, and other countries; holding company structure based in the Cayman Islands.

• Strategic collaborations with global partners leveraging proprietary technology platforms.

Financial performance and metrics

• Historical net losses with continued losses expected in the near future; limited operating history makes future performance difficult to predict.

• Cash payments of $24.5M (2022), $20.5M (2023), and $16.3M (2024) made to PRC subsidiary for R&D services.

Use of proceeds and capital allocation

• No proceeds will be received from the sale of shares by the selling shareholder; company will bear registration and related expenses.

• Net proceeds from prior equity financings used for R&D and operational funding.